Amgen’s (AMGN) injectable osteoporosis drug Prolia scored over the most-frequently used intravenous bisphosphonate zoledronic acid in improving bone mineral density in postmenopausal women with osteoporosis following previous treatment with oral bisphosphonates in a phase 4 study.